ANDA 62558, held by Pharmafair. Erythromycin Ethylsuccinate.
As of Nov 16, 2026, ANDA 62558 (Erythromycin Ethylsuccinate), held by Pharmafair, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Erythromycin EthylsuccinateEQ 400MG BASE/5ML ยท suspension;oral | Erythromycin Ethylsuccinate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters